16211 AML in older adults: Are outcomes age dependent? - 4-5pm (CDT) - November 17, 2016

Minneapolis, MN US
November 17, 2016

AML disease heterogeneity and diverse patient fitness levels have led to debate over therapeutic options for older adults. New research is clarifying the risks and benefits of treatment choices for the increasing number of patients over age 60 who are considering induction therapy and consolidative HCT. Using an interactive, case study-based format, presenters will discuss patient comorbidities, disease factors and assessment tools that influence treatment decision-making.

ACCME Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Medical College of Wisconsin and National Marrow Donor Program. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

AMA Credit Designation Statement:

The Medical College of Wisconsin designates this Enduring Material for a maximum of 1 AMA PRA Category 1 Credit(s) ™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals
The Medical College of Wisconsin designates this activity for up to 1 hours of participation for continuing education for allied health professionals.  

Questions?

If you have any questions regarding this activity, contact Nicole Heino, continuing education manager, Education and Training, NMDP/Be The Match at (800) 526-7809 ext. 4811, or email nheino@nmdp.org.

Target Audience

Hematologist
Oncologists
Nurse Practitioners
Physician Assistants
Allied Health Professionals 

Learning Objectives

At the conclusion of this activity, I will be able to:

  1. Apply evidence-based patient- and disease-specific prognostic factors at diagnosis to identify potential treatment options for patients with AML 
  2. Compare the risks and benefits of therapeutic options, including HCT, for older patients with AML 
  3. Cite recent clinical trial results and the impact of treatment timing and disease status on outcomes for older patients 
  4. Use patient education resources to support the needs of patients and caregivers in understanding treatment choices for older patients 
Additional information

CME Coordinator Contact Information

Name: 
Nicole Heino
Phone Number: 
+1 (763) 406-4811
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
11/17/2016
Course expires: 
12/30/2016
Event starts: 
11/17/2016 - 4:00pm
Event ends: 
11/17/2016 - 5:00pm
Cost:
$0.00
National Marrow Donor Program/Be The Match
500 N 5th Street
Minneapolis, MN 55401-1206
United States
Planning Committee:
Laura Michaelis, MD
Linda Burns, MD
Balkrishna Jahagirdar, MD
Sergio Giralt, MD
Navneet Majhail, MD, MS
Elizabeth Murphy, EdD, RN
Darlene Haven
Nicole Heino
Ellyce Hayes
Sara Roedl, PhD
Jackie Foster, MPH, RN, OCN
Ellen Denzen, MS
Heather Moore
Christa Meyer
 
 
Speakers

Fred Appelbaum, M.D. (moderator)
Fred Hutchinson Cancer Research Center

Laura C. Michaelis, M.D.
Medical College of Wisconsin, Froedrert Hospital

James Foran, M.D., FRCPC
Mayo Clinic – Jacksonville

 
 
All persons in control of content has no relevant financial relationships to disclose with the exception of the following persons;
 
NameCompanyRole
Sergio Giralt, MDCelgene, Sanofi, Jazz, Takeda, AmgenResearch, Advisory Board
Laura Michaelis, MDIncyte, Celgene, PfizerConsultant, Stock Owner
Navneet Majhail, MDAnthem Inc., SanofiConsultant, Speaker
Jackie Foster, MPH, RNPfizerStock Owner
James Foran, MDNovartis, Pfizer, KaryopharmAdvisory Board
Fred Applebaum, MDAdaptive Biotechnologies, Amgen, CelatorConsultant
 

In accordance with the ACCME®  Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Accreditation Period

Course opens: 
11/17/2016
Course expires: 
12/30/2016

Price

Cost:
$0.00
Please login or register to take this course.